Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
Oric Pharmaceuticals, Inc. Schedule 13G/A reports that Viking Global Investors and affiliated reporting persons beneficially own 8,264,607 shares of Common Stock, representing 7.8% of the class. The filing states 103,486,412 shares outstanding as of March 31, 2026 and that the reporting persons hold rights to purchase 2,440,074 shares upon exercise of pre-funded warrants. The amendment notes that David C. Ott retired effective March 31, 2026 and was removed as a reporting person. The disclosure cites Rule 13d-3 for beneficial ownership attribution and lists the related Viking entities and principals with shared voting and dispositive power over the reported shares.
ORIC Pharmaceuticals ownership update: A group led by Venrock Healthcare affiliates reports beneficial ownership of 4,319,765 shares of ORIC common stock, equal to 4.2% of the class. The percentage is calculated using 103,486,412 shares outstanding as of March 31, 2026.
The filing names the Reporting Persons (Venrock Healthcare Capital Partners III, VHCP Co-Investment Holdings III, Venrock Healthcare Capital Partners EG, VHCP Management III, VHCP Management EG, Nimish Shah and Bong Koh) and states shared voting and dispositive power over the reported shares. Ownership figures are shown as of March 31, 2026.
Oric Pharmaceuticals filed an Amendment No. 1 to a Schedule 13G/A reporting that Point72-affiliated filers hold 0% of the class. The cover-page figures are stated as of the close of business on March 31, 2026. The amendment lists Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons and provides a principal business address.
ORIC Pharmaceuticals reported that T. Rowe Price Associates, Inc. beneficially owned 5,387,783 shares of Common Stock, representing 5.4% of the class as of 03/31/2026. The filing lists sole voting power of 5,382,293 shares and sole dispositive power of 5,387,783. The filer includes a written statement denying beneficial ownership.
Pfizer Inc. reports beneficial ownership of 3,442,940 shares of ORIC Pharmaceuticals common stock, representing 3.3% of the outstanding class. The percent is calculated on 103,517,562 shares outstanding as of April 27, 2026, as reported on the cover of ORIC's Form 10‑Q for the quarter ended March 31, 2026.
The filing is a Schedule 13G/A amendment signed by Madelyn D. Purcell on behalf of Pfizer, listing Pfizer's sole voting and dispositive power over the reported shares and providing Pfizer's Delaware status and business address.
ORIC Pharmaceuticals, Inc. reported a net loss of $35.8M for the quarter ended March 31, 2026, compared with $30.0M a year earlier, as it increased investment in its lead oncology programs.
Research and development expenses rose to $31.4M from $24.6M, driven mainly by higher external costs for prostate cancer candidate rinzimetostat and lung cancer candidate enozertinib, while general and administrative expenses were stable at about $8.2M.
ORIC strengthened its balance sheet with $59.9M of net proceeds from at-the-market stock sales, helping lift total cash, cash equivalents and investments to $419.7M. Management believes this liquidity will fund the current operating plan into the second half of 2028 as the company prepares a Phase 3 trial for rinzimetostat and advances multiple Phase 1b studies for enozertinib.
ORIC Pharmaceuticals reported a first quarter 2026 net loss of $35.8 million, or $0.34 per share, as it advanced two oncology programs. The company selected a 400 mg once-daily dose of rinzimetostat with darolutamide for the Himalayas-1 Phase 3 registrational trial in post-abiraterone mCRPC, expected to start in 1H 2026, supported by favorable safety and landmark rPFS data.
ORIC also reported early rinzimetostat data in post-AR inhibitor mCRPC and continued Phase 1b development of enozertinib across multiple NSCLC settings, with several data updates anticipated in 2H 2026. Cash, cash equivalents and investments were $419.7 million as of March 31, 2026, including $59.9 million raised via an ATM program, which ORIC expects will fund operations into 2H 2028.
ORIC Pharmaceuticals is asking stockholders to vote at its virtual 2026 annual meeting on June 18, 2026. Holders of 103,517,562 shares of common stock as of April 20, 2026 can vote online. The ballot includes electing two Class III directors (Jacob M. Chacko and Mardi C. Dier), ratifying KPMG LLP as auditor for 2026, approving an amended 2020 Equity Incentive Plan that reduces the annual evergreen increase to 4%, caps incentive stock options at 10,000,000 shares and removes the board’s unilateral ability to run option exchange programs, plus advisory votes on executive pay and the frequency of future say‑on‑pay votes. The board describes its largely independent, staggered board structure and details higher 2026 cash retainers and larger option grants for non‑employee directors.
ORIC Pharmaceuticals reported updated Phase 1b dose optimization data for rinzimetostat (ORIC-944), its PRC2 inhibitor, in metastatic castration-resistant prostate cancer, and is advancing a 400 mg once-daily dose into Phase 3 in combination with darolutamide.
The 400 mg regimen showed strong prostate-specific antigen (PSA) responses in post-abiraterone patients, with 47% achieving PSA50 and 33% achieving confirmed PSA50, alongside broad and deep PSA declines. Safety data across post-abiraterone and broader post-ARPI populations showed most treatment-related adverse events were Grade 1–2, no Grade 5 events, and only 6–11% Grade 3 events at 400 mg, supporting long-term dosing and adherence.
Exposure–response analyses across 113 patients found no correlation between higher exposure and better efficacy, but higher exposure was associated with more toxicity and dose modifications, reinforcing 400 mg as the recommended Phase 3 dose. Early landmark radiographic progression-free survival rates compared favorably to competitor regimens while using a lower-intensity schedule. The company also highlighted a second late-stage candidate, enozertinib (ORIC-114), and reported cash and investments of about $392 million as of December 31, 2025, plus roughly $20 million raised afterward, providing runway into the second half of 2028.